![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
FORMULATION AND EVALUATION OF TRANSDERMAL PATCH OF ORLISTAT SOLID DISPERSION
Manjunatha T., Manjunath K.* and Suresh V. Kulkarni
ABSTRACT
Anti obesity medications are pharmacological agents that reduce or control body weight. Transdermal drug delivery system (TDDS) was designed to sustain the release and improve the bioavailability of drug and patient compliance. The aim of this research work was to formulate transdermal formulation of orlistat for treatment of obesity. Transdermal patches were prepared by solvent casting method using different polymers like PEG 4000 carrier using for drug solubility enhancement, HPMC K100 and Chitosan these two polymers are in presence or absence of permeation enhancersi.e. tween 80 and oleic acid and propylene glycol as a plasticizer. There was no interaction found between the drug and the polymers by the FTIR and DSC studies. The transdermal patches uniform in their physical characteristics with low moisture content and moisture uptake. The folding endurance values >250 revealed that the prepared patches were having the capability to withstand the mechanical pressure along with good flexibility. The transdermal films prepared with HPMC K100 showed increased tensile strength compared to formulation prepared with chitosan. The in-vitro drug release studies showed that the optimized formulation F3 showed nearly complete release (96.61±1.86%) at the end of 24 hours. The release kinetic studies showed that the release was Higuchi kinetics model and the n values obtained from the Korsmeyer-Peppas model indicated the release mechanism wasnon-Fickiantype(n-value of F3 was 0.654).Orlistat transdermal film formulation was physicochemically stable throughout study period. Keywords: Orlistat, Transdermal patches, Solvent casting method, Permeation enhancers, FTIR, in vitro release. [Download Article] [Download Certifiate] |